AU2022217475A1 - Amiselimod for preventing, treating, or ameliorating ulcerative colitis - Google Patents

Amiselimod for preventing, treating, or ameliorating ulcerative colitis Download PDF

Info

Publication number
AU2022217475A1
AU2022217475A1 AU2022217475A AU2022217475A AU2022217475A1 AU 2022217475 A1 AU2022217475 A1 AU 2022217475A1 AU 2022217475 A AU2022217475 A AU 2022217475A AU 2022217475 A AU2022217475 A AU 2022217475A AU 2022217475 A1 AU2022217475 A1 AU 2022217475A1
Authority
AU
Australia
Prior art keywords
dose
subject
amiselimod
administration
administration period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022217475A
Other languages
English (en)
Inventor
Zeev HEIMANSON
Jimin Lee
Ezra R. LOWE
Neal SLATKIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch Health Ireland Ltd
Original Assignee
Bausch Health Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch Health Ireland Ltd filed Critical Bausch Health Ireland Ltd
Publication of AU2022217475A1 publication Critical patent/AU2022217475A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Luminescent Compositions (AREA)
  • Cereal-Derived Products (AREA)
AU2022217475A 2021-02-08 2022-02-08 Amiselimod for preventing, treating, or ameliorating ulcerative colitis Pending AU2022217475A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147060P 2021-02-08 2021-02-08
US63/147,060 2021-02-08
PCT/EP2022/053030 WO2022167690A1 (en) 2021-02-08 2022-02-08 Amiselimod for preventing, treating, or ameliorating ulcerative colitis

Publications (1)

Publication Number Publication Date
AU2022217475A1 true AU2022217475A1 (en) 2023-08-24

Family

ID=80447376

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022217475A Pending AU2022217475A1 (en) 2021-02-08 2022-02-08 Amiselimod for preventing, treating, or ameliorating ulcerative colitis

Country Status (9)

Country Link
US (1) US20240299318A1 (https=)
EP (1) EP4288041A1 (https=)
JP (1) JP2024506041A (https=)
CN (1) CN116940350A (https=)
AU (1) AU2022217475A1 (https=)
CA (1) CA3207440A1 (https=)
MX (1) MX2023009249A (https=)
TW (1) TW202245742A (https=)
WO (1) WO2022167690A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025134072A1 (en) * 2023-12-21 2025-06-26 Bausch Health Ireland Limited Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
BRPI0619894B8 (pt) 2005-12-15 2021-05-25 Mitsubishi Tanabe Pharma Corp composto de amina e composição farmacêutica
JP5657565B2 (ja) 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
MA40774A (fr) * 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
PL3242666T3 (pl) * 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
JP2018527406A (ja) * 2015-08-11 2018-09-20 アカール ファーマ ピーティーワイ リミテッドＡｋａａｌ Ｐｈａｒｍａ Ｐｔｙ Ｌｔｄ Ｓ１ｐ受容体モジュレーターを含む組成物
WO2020051568A1 (en) * 2018-09-08 2020-03-12 Wen Tan NEW USE OF R-ENANTIOMER OF ADRENERGIC β2 RECEPTOR AGONISTS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND ITS EXTRA INTESTINAL MANIFESTATIONS

Also Published As

Publication number Publication date
EP4288041A1 (en) 2023-12-13
CN116940350A (zh) 2023-10-24
CA3207440A1 (en) 2022-08-11
TW202245742A (zh) 2022-12-01
JP2024506041A (ja) 2024-02-08
WO2022167690A1 (en) 2022-08-11
MX2023009249A (es) 2023-10-23
US20240299318A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
JP6244497B1 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
JP6309454B2 (ja) 癌の併用処置
JP4938905B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
KR102495432B1 (ko) 중등증 내지 중증의 호산성 천식을 치료하기 위한 레슬리주맙의 용도
WO2010056910A2 (en) Methods of treating cardiovascular disorders
TW200800206A (en) Methods for determining how to treat congestive heart failure
WO2023231730A2 (zh) 使用mazdutide的治疗方法
JP2025148495A (ja) Ｂ因子阻害剤の使用方法
JP2024531314A (ja) 小児ｍｓを治療するためのオファツムマブ
US20240299318A1 (en) Amiselimod for preventing, treating or ameliorating ulcerative colitis
JP2025106329A (ja) ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法
WO2025134072A1 (en) Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod
Noval Rivas et al. Kawasaki Disease Vasculitis: From Diagnosis to New Concepts in Pathophysiology and Therapeutic Approaches
US20230151093A1 (en) Methods of treating immune mediated pulmonary injury
EA051860B1 (ru) Способ профилактики, лечения или облегчения язвенного колита
HK40094222A (zh) 预防、治疗或改善溃疡性结肠炎的阿米莫德
JP2021510157A (ja) 内皮細胞機能障害を調節するためのｒｐｓ２ペプチドの使用
JP2012031141A (ja) 骨髄異形性症候群を治療するための組成物および方法
WO2025209479A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
JP2023502015A (ja) マルチターゲット型プロテインキナーゼ阻害剤の用途
KR20220074913A (ko) S1p1 수용체와 관련된 상태를 치료하는 방법
EP4616867A1 (en) Combination of endothelin receptor antagonist and glucocorticoid for treating iga nephropathy
Home Highlights in Ulcerative Colitis From the 18th Congress of ECCO
TW202539688A (zh) 使用索樂匹尼布處置溫型自體免疫性溶血性貧血的方法
KR20220128984A (ko) sGC 자극제를 사용한 당뇨병성 신장병증의 치료